← Back to Clinical Trials
Recruiting NCT03775837

NCT03775837 Effect of Panax Ginseng C.A. Mey Extract on Liver Function in Adults

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03775837
Status Recruiting
Phase
Sponsor Pusan National University Yangsan Hospital
Condition Liver Diseases
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2018-12-01
Primary Completion 2025-12-30

Eligibility & Interventions

Sex All sexes
Min Age 19 Years
Max Age 75 Years
Study Type INTERVENTIONAL
Interventions
Panax Ginseng C.A. Mey Extract groupPlacebo group

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2018-12-01 with a primary completion date of 2025-12-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of Panax Ginseng C.A. Mey Extract on liver function in adults for 8 weeks.

Eligibility Criteria

Inclusion Criteria: * ALT ranging from upper limit of reference to three times of upper limit Exclusion Criteria: * Abnormal liver or renal function (i.e., serum aminotransferase activity \> 3 times of upper limit of reference range and serum creatinine concentrations \> 1.2 mg/dL) * Diabetes (diagnosed clinically or fasting glucose level \> 126 mg/dL) * History of viral hepatitis or cancer * Uncontrolled hypertension * History of serious cardiac disease such as angina or myocardial infarction * History of gastrectomy * History of medication for psychiatric disease * Administration of oriental medicine including herbs within the past 4 weeks

Contact & Investigator

Central Contact

Sang Yeoup Lee

✉ saylee@pnu.edu

📞 360-2860

Principal Investigator

Sang Yeoup Lee

PRINCIPAL INVESTIGATOR

Pusan National University Yangsan Hospital

Frequently Asked Questions

Who can join the NCT03775837 clinical trial?

This trial is open to participants of all sexes, aged 19 Years or older, up to 75 Years, studying Liver Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03775837 currently recruiting?

Yes, NCT03775837 is actively recruiting participants. Contact the research team at saylee@pnu.edu for enrollment information.

Where is the NCT03775837 trial being conducted?

This trial is being conducted at Yangsan, South Korea.

Who is sponsoring the NCT03775837 clinical trial?

NCT03775837 is sponsored by Pusan National University Yangsan Hospital. The principal investigator is Sang Yeoup Lee at Pusan National University Yangsan Hospital. The trial plans to enroll 60 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology